Blood Coagulation Factor Ii Or Factor Ii + Vii + Ix + X, I.e., Prothrombin Complex Or Factor Patents (Class 530/384)
-
RECOMBINANT VITAMIN K DEPENDENT PROTEINS WITH HIGH SIALIC ACID CONTENT AND METHODS OF PREPARING SAME
Publication number: 20100081187Abstract: Methods of isolating highly sialylated recombinant vitamin K dependent proteins, particularly Factor IX, by chromatographic methods are described. The highly sialylated recombinant proteins are characterized. The improved Factor IX has at least 62% N-glycosylation with 3 or 4 sialic acid residues and improved bioavailability and pharmokinetic properties.Type: ApplicationFiled: April 28, 2008Publication date: April 1, 2010Inventors: Michael J. Griffith, William N. Drohan, Marian J. Drohan -
Patent number: 7671013Abstract: The present invention relates to the use of coagulation proteins and complexes thereof with anticoagulation proteins for the lysis of blood clots or other applications affected by accelerated plasmin production. More specifically, the present invention provides a method for accelerating the dissolution of a blood clot through the administration of at least one coagulation protein, with or without being in complex with a serpin, comprising a basic C-terminal amino acid, wherein the coagulation protein may be a derivative of Factor X or Factor V or a combination thereof. Pharmaceutical compositions for the treatment and prophylaxis of blood clots are also provided, wherein, the methods and products of the present invention advantageously accelerate clot dissolution while potentially minimizing the adverse side-effects, such as hemorrhaging, seen with other clot dissolving agents. The present invention also provides a method for detecting a fibrinolytic potential in a subject.Type: GrantFiled: June 13, 2006Date of Patent: March 2, 2010Assignee: Canadian Blood Services, Inc.Inventor: Edward L. G. Pryzdial
-
Publication number: 20100047428Abstract: The invention is related to a process for extracting at least one protein present in milk, said protein exhibiting an affinity for the complexed or non-complexed calcium ions of said milk, comprising the following steps consisting of: a) releasing the protein by precipitation of calcium compounds obtained by contacting the milk with a soluble salt, the anion of which is selected for its capability to form said insoluble calcium compounds in such a medium, in order to obtain in this way a protein-enriched liquid phase, b) separating the protein-enriched liquid phase from the precipitate of calcium compounds, said liquid phase being, moreover, separated in a lipidic phase and in a non-lipidic aqueous phase comprising the protein, and c) recovering the non-lipidic aqueous phase comprising the protein.Type: ApplicationFiled: May 31, 2007Publication date: February 25, 2010Applicant: LFB BIOTECHNOLOGIESInventors: Alain Lejars, Michel Nogre, Michael Tellier
-
Patent number: 7662923Abstract: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.Type: GrantFiled: November 2, 2006Date of Patent: February 16, 2010Assignee: Regents of the University of MinnesotaInventor: Gary L Nelsestuen
-
Publication number: 20100028939Abstract: This invention relates to novel compounds, methods for selective chemical conjugation of protractor molecules and the use thereof for diagnostic and/or therapeutic purposes.Type: ApplicationFiled: April 1, 2008Publication date: February 4, 2010Applicant: Novo Nordisk Healthcare A/GInventors: Carsten Behrens, Patrick William Garibay, Magali Zundel, Niels Kristian Klausen, Soren E. Bjorn
-
Publication number: 20090298762Abstract: Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the unconjugated biologically active polypeptide or protein. Also disclosed are methods of making and using the conjugated proteins, as well as methods for determining whether a given conjugate exhibits a modified half life relative to the intrinsic half life of the unconjugated polypeptide.Type: ApplicationFiled: October 14, 2008Publication date: December 3, 2009Applicant: Cell Therapeutics, Inc.Inventors: Marc Besman, Stewart Chipman, David Leung, Jack Singer
-
Patent number: 7612188Abstract: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.Type: GrantFiled: November 2, 2006Date of Patent: November 3, 2009Assignee: Regents of the University of MinnesotaInventor: Gary L Nelsestuen
-
Patent number: 7589178Abstract: The invention relates to chimeric proteins comprising an artificial sequence for cleavage by thrombin, in which the activation peptide is fibrinopeptide A. Preferably, said chimeric proteins are derived from the zymogen of a serine protease such as PC or FX, by replacing the activation peptide of said zymogen with fibrinopeptide A, or a portion thereof, comprising at least amino acids P10 to P1 of said fibrinopeptide.Type: GrantFiled: October 18, 2002Date of Patent: September 15, 2009Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Bernard Le Bonniec, Pierre-Emmanuel Marque, Virginie Louvain, Claire Calmel, Elsa Bianchini, Martine Aiach
-
Publication number: 20090227504Abstract: The invention concerns a preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked and/or serine-linked oligosaccharide chains, and wherein at least one oligosaccharide group is covalently attached to at least one polymeric group.Type: ApplicationFiled: February 13, 2009Publication date: September 10, 2009Applicant: Novo Nordisk A/SInventors: Niels Kristian Klausen, Soren Bjorn, Carsten Behrens, Patrick William Garibay
-
Publication number: 20090221800Abstract: The present invention relates to a process for the production of recombinant polypeptides in leukocytes.Type: ApplicationFiled: May 13, 2009Publication date: September 3, 2009Applicant: Novo Nordisk HealthCare A/GInventors: Jan Nehlin, Ivan Svendsen
-
Patent number: 7579444Abstract: Conjugates of a Factor IX moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided (among other things) are compositions comprising the conjugates, methods of making the conjugates, and methods of administering to a patient compositions comprising the conjugates.Type: GrantFiled: June 30, 2005Date of Patent: August 25, 2009Assignee: Nektar Therapeutics AL, CorporationInventors: Mary J. Bossard, Gayle Stephenson
-
Patent number: 7553934Abstract: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.Type: GrantFiled: October 6, 2006Date of Patent: June 30, 2009Assignee: Regents of the University of MinnesotaInventor: Gary L Nelsestuen
-
Patent number: 7553935Abstract: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.Type: GrantFiled: October 6, 2006Date of Patent: June 30, 2009Assignee: Regents of the University of MinnesotaInventor: Gary L Nelsestuen
-
Patent number: 7544774Abstract: The present invention is directed to an isolated peptide that functionally mimics a binding site for a monoclonal antibody, the monoclonal antibody recognizing an epitope within the human platelet glycoprotein Ib/IX complex. This peptide is called a mimotope. The invention also provides an isolated molecule capable of binding to the peptide, or the mimotope, which molecule can be an antibody, a second peptide, a carbohydrate, a DNA molecule, an RNA molecule, or other naturally or chemically synthesized molecules. This isolated molecule is called an anti-mimotope. Mimotopes mimicking the binding site for monoclonal antibody C-34 and SZ-2, as well as anti-mimotopes to the C-34 mimotopes, are specifically provided.Type: GrantFiled: December 3, 2004Date of Patent: June 9, 2009Assignee: The Research Foundation of State University of New YorkInventors: Jonathan L. Miller, Vicki A. Lyle
-
Publication number: 20090137001Abstract: The present invention provides for a process for preparing a recombinant human thrombin. A process for preparing a recombinant human thrombin which comprises: (1) obtaining a transfectant cell producing a human prothrombin by introducing an expression vector, wherein a gene fragment coding for a human prothrombin gene is incorporated, into an animal cell; (2) purifying a human prothrombin from the culture of the transfectant cell above by an anion exchanger; (3) converting the purified human prothrombin into a human thrombin by subjecting said human prothrombin to the action of ecarin; and (4) purifying the human thrombin from the solution after treatment with ecarin by an affinity method using benzamidine and a cation exchanger, and human thrombin obtained by said process, and a CHO cell that produces human prothrombin.Type: ApplicationFiled: September 29, 2006Publication date: May 28, 2009Inventors: Tatsufumi Onchi, Yo Nakahara, Takayuki Imamura, Toshinobu Nouchi, Hiroshi Nakatake
-
Publication number: 20090130060Abstract: The present invention relates to modified cDNA sequences coding for vitamin K-dependent polypeptides, in particular human Factor VII, human Factor VIIa, human Factor IX and human protein C and their derivatives with improved stability and extended plasma half life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.Type: ApplicationFiled: August 10, 2005Publication date: May 21, 2009Applicant: CSL BEHRING GMBHInventors: Thomas Weimer, Stefan Schulte, Kay Hofmann, Hans-Peter Hauser
-
Patent number: 7531513Abstract: The therapeutic preparation of FVIIa having a purity of at least 1000 IU/mg of protein is characterized in that said preparation is free of proteins of non-human origin. In the method for obtaining FVII, purification starts from FrII+III, FrIII or equivalent of Cohn fractioning and comprises precipitation with PEG, chromatography and its subsequent activation.Type: GrantFiled: February 8, 2007Date of Patent: May 12, 2009Assignee: Grifols, S.A.Inventors: Salvador Grancha Gamon, Pere Ristol Debart, Juan Ignacio Jorquera Nieto
-
Publication number: 20090104121Abstract: Provided herein are methods and compositions for the in vitro formation of multi subunit biological platforms. The biological platforms may be used to screen chemical or biological compounds, in particular compounds that may disrupt or otherwise affect the formation of the multi subunit complexes, or disrupt already-formed in vitro assembled multi subunit complexes. Also provided herein are methods and compositions for the in vivo formation of multi-subunit biological complexes. The methods and compositions described herein may be used to develop animal models of diseases or disorders.Type: ApplicationFiled: September 29, 2008Publication date: April 23, 2009Applicant: Plaxgen, IncInventor: Shanmugavel Madasamy
-
Patent number: 7521210Abstract: The invention provides a method for large-scale production of a polypeptide, such as a Factor VII or Factor VIIa polypeptide, in eukaryote cells, such as mammalian cells, contained in a culture liquid, said method comprising: monitoring the concentration of dissolved CO2 in the culture liquid, and constantly or intermittently sparging atmospheric air through the culture liquid, wherein the sparging rate of the air is controlled in relation to the monitored concentration of dissolved CO2 in the culture liquid. The method reduces or eliminates the use of bases while providing an excellent pH control. The invention also provides a culture vessel suitable for the methods.Type: GrantFiled: March 30, 2006Date of Patent: April 21, 2009Assignee: Novo Nordisk Healthcare A/GInventor: Ida Mølgaard Knudsen
-
Patent number: 7517974Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: GrantFiled: March 30, 2006Date of Patent: April 14, 2009Assignee: Bayer Healthcare LLCInventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
-
Publication number: 20090088370Abstract: The present invention provides a method for increasing the yield of a protein produced by cultivating eukaryotic cells and adding an ionic substance to the culture medium prior to harvest of the protein. Suitable ionic substances are the salts of the Hofmeister series, amino acids and peptone.Type: ApplicationFiled: March 29, 2006Publication date: April 2, 2009Applicant: Octapharma AGInventor: Stefan Winge
-
Patent number: 7507412Abstract: The present invention relates to Glycoprotein VI (GPVI) fusion proteins (GPVI-fusion proteins) comprising a tag like myc, GST, HA, FLAG, STREP but preferably a Immunoglobulin molecule (Ig), more preferably a Fc portion of said Ig and a protein or oligopeptide having the biological activity of GPVI (GPVI-like protein) which is binding to collagen and their use in methods and kits for the screening of potential agonists or antagonists for GPVI-colagen and/or platelet-collagen interaction is disclosed. Further, pharmaaceutical compositions and therapeutic methods are provided comprising such GPVI-fusion proteins for the treatment of thrombotic and cardiovascular events and disorders related to GPVI-collagen and/or platelet-collagen interactions.Type: GrantFiled: July 12, 2002Date of Patent: March 24, 2009Assignee: Merck Patent GmbHInventors: Christa Burger, Johannes Gleitz, Mathias Frech
-
Patent number: 7501493Abstract: A method for preparing a stable dried composition of blood factor product containing a stabilizing amount of trehalose in the absence of a stabilizing amount of albumin is disclosed.Type: GrantFiled: August 20, 2007Date of Patent: March 10, 2009Assignee: Quadrant Drug Delivery LimitedInventor: Bruce Joseph Roser
-
Publication number: 20090047251Abstract: Conjugates of hydroxyalkyl starch and a protein are provided herein. The conjugates are formed by a convalent linkage between the hydroxyalkyl starch or a derivative of the hydroxyalkyl starch and the protein. Methods of producing the conjugates and the use of the conjugates also are provided herein.Type: ApplicationFiled: September 8, 2006Publication date: February 19, 2009Inventors: Wolfram Eichner, Martin Schimmel, Frank Hacket, Elmar Kraus, Norbert Zander, Ronald Frank, Harald Conradt, Klaus Langer, Michele Orlando, Klaus Sommermeyer
-
Publication number: 20090041744Abstract: The present invention relates to dimeric or multimeric FVIIa compounds comprising at least two FVIIa polypeptides covalently connected such as to retain the intrinsic catalytic activity of the FVIIa polypeptides.Type: ApplicationFiled: June 19, 2006Publication date: February 12, 2009Applicant: Novo Nordisk HealthCare A/GInventors: Henrik Ostergaard, Henning Ralf Stennicke
-
Patent number: 7479551Abstract: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.Type: GrantFiled: October 6, 2006Date of Patent: January 20, 2009Assignee: Regents of the University of MinnesotaInventor: Gary L Nelsestuen
-
Publication number: 20080318850Abstract: The present invention provides conjugates between Factor IX and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.Type: ApplicationFiled: May 6, 2004Publication date: December 25, 2008Applicant: Neose Technologies, Inc.Inventors: Shawn DeFrees, Robert J. Bayer, Caryn Bowe, Krishnasamy Panneerselvam
-
Publication number: 20080305518Abstract: The present invention relates to compositions comprising glycoproteins having altered patterns of O-linked glycosylation, in particular Factor VII, Factor IX, and methods for making these.Type: ApplicationFiled: May 3, 2005Publication date: December 11, 2008Applicant: NOVO NORDISK HEALTHCARE A/GInventors: Niels Kristian Klausen, Daniel Rasmussen
-
Publication number: 20080305991Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.Type: ApplicationFiled: January 23, 2007Publication date: December 11, 2008Applicant: Neose Technologies, Inc.Inventors: Shawn DeFrees, David Zopf, Robert J. Bayer, Caryn Bowe, David Hakes, Xi Chen
-
Publication number: 20080280818Abstract: The present invention provides sequon polypeptides with an amino acid sequence including one or more exogenous O-linked glycosylation sequence of the invention. In addition, the present invention provides methods of making polypeptide conjugates as well as methods of using such conjugates and their pharmaceutical compositions. The invention further provides libraries of sequon polypeptides, wherein each member of such library includes at least one exogenous O-linked glycosylation sequence of the invention. Also provided are methods of making and using such libraries.Type: ApplicationFiled: July 23, 2007Publication date: November 13, 2008Applicant: Neose Technologies, Inc.Inventor: Shawn DeFrees
-
Publication number: 20080227205Abstract: The invention provides methods and compositions for in vivo incorporation of non-naturally encoded amino acids into polypeptides by Pseudomonas species and strains derived therefrom. Also provided are compositions including proteins with non-naturally encoded amino acids made by Pseudomonas species and strains derived therefrom.Type: ApplicationFiled: June 2, 2006Publication date: September 18, 2008Applicant: AMBRX, INC.Inventor: Ho Sung Cho
-
Publication number: 20080207879Abstract: The present invention relates to a method for the purification of rFIX using anion exchange chromatography in the pseudo-affinity mode, wherein said method comprises a wash step with a wash buffer having a salt concentration of more than 200 mM. The purification according to the invention provides a method to enrich rFIX molecules which have been posttranslationally modified by sulfation and/or phosphorylation. The present invention further relates to purified rFIX compositions enriched in monosulfated and/or monophosphorylated rFIX molecules.Type: ApplicationFiled: February 26, 2008Publication date: August 28, 2008Applicants: Baxter International Inc., Baxter Healthcare S.A.Inventors: Mitterer Artur, Hasslacher Meinhard, Fiedler Christian
-
Publication number: 20080200651Abstract: The present invention relates to method for selective reduction and derivatization of recombinantly prepared engineered proteins comprising at least one non-native cysteine, wherein the reduction reaction is conducted in the presence of a redox buffer or in the presence of a triarylphosphine reducing agent.Type: ApplicationFiled: June 19, 2006Publication date: August 21, 2008Applicant: Novo Nordisk HealthCare A/GInventors: Henrik Ostergaard, Anders Klarskov Petersen
-
Patent number: 7381796Abstract: A method for preparing a stable dried composition of blood factor product containing a stabilizing amount of trehalose in the absence of a stabilizing amount of albumin is disclosed.Type: GrantFiled: March 23, 2007Date of Patent: June 3, 2008Assignee: Quadrant Drug Delivery LimitedInventor: Bruce Joseph Roser
-
Patent number: 7314917Abstract: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.Type: GrantFiled: April 21, 2004Date of Patent: January 1, 2008Assignee: Regents of the University of MinnesotaInventor: Gary L. Nelsestuen
-
Patent number: 7300922Abstract: The biological activity of nucleic acid ligand is regulated (i.e. enhanced or inhibited) in vivo to produce a desired biological effect. This is accomplished through the administration of a modulator, or regulator, that changes the binding of the nucleic acid ligand for its target or that degrades or otherwise cleaves, metabolizes or breaks down the nucleic acid ligand while the ligand is still exerting its effect. Modulators of the present invention can be administered in real time as needed based on various factors, including the progress of the patient, as well as the physician's discretion in how to achieve optimal therapy. Thus, this invention provides for the first time a regulatable therapeutic regime in the course of nucleic acid ligand therapy.Type: GrantFiled: May 28, 2002Date of Patent: November 27, 2007Assignee: Duke UniversityInventors: Bruce A. Sullenger, Christopher P Rusconi
-
Patent number: 7253262Abstract: A stable blood factor composition contains a stabilizing amount of trehalose in the absence of human serum albumin to provide a product stable at up to 60° C.Type: GrantFiled: June 25, 2001Date of Patent: August 7, 2007Assignee: Quandrant Drug Delivery LimitedInventor: Bruce Joseph Roser
-
Patent number: 7247708Abstract: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.Type: GrantFiled: November 18, 2002Date of Patent: July 24, 2007Assignee: Regents of the University of MinnesotaInventor: Gary L. Nelsestuen
-
Patent number: 7244825Abstract: A stable blood factor composition contains a stabilising amount of trehalose in the absence of human serum albumin to provide a product stable at up to 60° C.Type: GrantFiled: September 8, 2003Date of Patent: July 17, 2007Assignee: Quadrant Drug Delivery LimitedInventor: Bruce Joseph Roser
-
Patent number: 7244824Abstract: A stable blood factor composition contains a stabilizing amount of trehalose in the absence of human serum albumin to provide a product stable at up to 60° C.Type: GrantFiled: October 8, 2003Date of Patent: July 17, 2007Assignee: Quadrant Drug Delivery LimitedInventor: Bruce Joseph Roser
-
Patent number: 7220836Abstract: A stable blood factor composition contains a stabilising amount of trehalose in the absence of human serum albumin to provide a product stable at up to 60° C.Type: GrantFiled: October 6, 2003Date of Patent: May 22, 2007Assignee: Quadrant Drug Delivery LimitedInventor: Bruce Joseph Roser
-
Patent number: 7220837Abstract: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.Type: GrantFiled: April 28, 2000Date of Patent: May 22, 2007Assignee: Regents of the University of MinnesotaInventor: Gary L. Nelsestuen
-
Patent number: 7220569Abstract: Nucleic acids encoding factor X analogues are provided that have a modification in the region of the natural Factor Xa activation cleavage site. The modification results in a processing site for a protease not naturally cleaving in this region of the Factor X sequence.Type: GrantFiled: April 4, 2003Date of Patent: May 22, 2007Assignee: Baxter AktiengesellschaftInventors: Michele Himmelspach, Uwe Schlokat, Friedrich Dorner, Andreas Fisch, Johann Eibl
-
Patent number: 7217794Abstract: The present invention provides compounds that inhibit Factor XIa and methods of preventing or treating undesired thrombosis by administering a compound of the invention to a mammal. The invention also provides three-dimensional structures of Factor XIa and methods for designing or selecting additional Factor XIa inhibitors using these structures.Type: GrantFiled: April 2, 2004Date of Patent: May 15, 2007Assignee: Daiamed, Inc.Inventors: Sherin S. Abdel-Meguid, Robert E. Babine, Hongfeng Deng, Lei Jin, Jian Lin, Scott R. Magee, Harold V. Meyers, Pramod Pandey, Michael J. Rynkiewicz, David T. Weaver, Zihong Gho, Thomas D. Bannister
-
Patent number: 7179617Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.Type: GrantFiled: April 9, 2003Date of Patent: February 20, 2007Assignee: Neose Technologies, Inc.Inventors: Shawn DeFrees, David Zopf, Robert Bayer, Caryn Bowe, David James Hakes, Xi Chen
-
Patent number: 7173000Abstract: A modified factor VIIa is provided. The modified factor has increased amidolytic activity in the absence of T.F. and a higher affinity for T.F. when compared to the native factor VIIa but does not have substantially altered proteolytic activity when bound to T.F. Nucleic acid molecules that encode the factor, expression vectors that contain the nucleic acid molecules, cells that contain the nucleic acid molecules, and cells transformed with the expression vector are also provided. In a preferred embodiment, the modified factor is a human factor VIIa.Type: GrantFiled: November 9, 2001Date of Patent: February 6, 2007Assignee: The Scripps Research InstituteInventors: Wolfram Ruf, Ramona J. Petrovan
-
Patent number: 7166709Abstract: A process for preparing a hemostatically active preparation containing von Willebrand factor (vWF) from a fraction of human plasma by chromatographic purification of a vWF-containing plasma fraction on an anion-exchange material which has the anion-exchanging groups on grafted polymeric structures (tentacle materials), collecting a vWF-containing fraction, followed by purification of said fraction using gel permeation to prepare a purified thermally stable vWF-containing preparation; and heating the preparation for inactivating viruses.Type: GrantFiled: April 4, 2001Date of Patent: January 23, 2007Assignee: Octapharma AGInventors: Djuro Josic, Monika Stadler, Gerhard Gruber
-
Patent number: 7125841Abstract: The present invention is related to a novel composition of matter and methods of using the same. More particularly, the invention describes mutant human factor IX which has an increased resistance to inhibition by heparin. Methods of making and using this composition for the therapeutic intervention of hemophilia are disclosed.Type: GrantFiled: November 13, 2001Date of Patent: October 24, 2006Assignee: The University of Texas SystemsInventor: John P. Sheehan
-
Patent number: 7078479Abstract: The present invention relates to a composition comprising factor VII or a factor VII-related polypeptide and alpha2-antiplasmin or an alpha2-antiplasmin-related polypeptide, and the use thereof for treating bleeding episodes.Type: GrantFiled: November 4, 2002Date of Patent: July 18, 2006Assignee: Novo Nordisk HealthCare A/GInventor: Rasmus Rojkjaer
-
Patent number: 7026524Abstract: The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as nucleic acid constructs encoding such variants, vectors and host cells comprising and expressing the nucleic acid, pharmaceutical compositions, uses and methods of treatment.Type: GrantFiled: November 15, 2002Date of Patent: April 11, 2006Assignee: Novo Nordisk Healthcare A/GInventors: Egon Persson, Ole Hvilsted Olsen